For research use only. Not for therapeutic Use.
SC-43(Cat No.:I010728), a Sorafenib derivative, is a potent and orally active SHP-1 (PTPN6) agonist. It inhibits STAT3 phosphorylation, induces cell apoptosis, and exhibits anti-proliferative effects in cholangiocarcinoma (CCA) cell lines. SC-43 activates SHP-1 by binding to its N-SH2 domain and relieving autoinhibition, resulting in downstream downregulation of cyclin B1 and Cdc2. In animal studies, SC-43 inhibits xenograft tumor growth, reduces p-STAT3 levels, and elevates SHP-1 activity. These findings suggest that SC-43 has potential as an anti-fibrotic and anticancer agent, particularly in CCA. Further research is needed to explore its therapeutic applications.
| Catalog Number | I010728 |
| CAS Number | 1400989-25-4 |
| Molecular Formula | C₂₁H₁₃ClF₃N₃O₂ |
| Purity | ≥95% |
| Target | Stem Cell/Wnt |
| IUPAC Name | 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[3-(4-cyanophenoxy)phenyl]urea |
| InChI | InChI=1S/C21H13ClF3N3O2/c22-19-9-6-15(11-18(19)21(23,24)25)28-20(29)27-14-2-1-3-17(10-14)30-16-7-4-13(12-26)5-8-16/h1-11H,(H2,27,28,29) |
| InChIKey | QIBWSQJZKMUZAK-UHFFFAOYSA-N |
| SMILES | C1=CC(=CC(=C1)OC2=CC=C(C=C2)C#N)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F |
| Reference | [1]. Ming-Hung Hu, et al. Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma. Oncotarget. 2017 May 10;8(39):65077-65089.<br>[2]. Tung-Hung Su, et al. Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis. Sci Rep. 2017 May 11;7(1):1728. |
